An Oncology Nurses’ Guide to New Targeted Agents for Metastatic Colorectal Cancer

Keith McIntyre

colorectal cancer, regorafenib, ziv-aflibercept, adverse effects, nurses, hand-foot syndrome
CJON 2015, 19(5), 571-579. DOI: 10.1188/15.CJON.571-579

Background: Colorectal cancer (CRC) that has metastasized before being discovered, or reoccurs following surgery, remains a major treatment challenge. Trials have established the usefulness of antiangiogenic agents and new regimens in prolonging survival in patients with advanced disease. In the United States, the antiangiogenic agents approved for treating metastatic CRC often are combined with traditional chemotherapeutic agents and include bevacizumab (Avastin®), ziv-aflibercept (Zaltrap®), and regorafenib (Stivarga®).

Objectives: This article reviews factors that guide the development of a nursing plan for monitoring and managing patients who are receiving antiangiogenic therapies.

Methods: Regorafenib and ziv-aflibercept, two newer agents that nurses and other healthcare professionals may have had less experience with, were reviewed.

Findings: The key to maximizing the potential benefit of these agents is understanding where these new therapies fit in the overall scheme of treatment options and how to help patients tolerate treatment.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.